Medisan(SZ:002900)2022-04-26 16:00Financial Performance - The company's operating revenue for 2021 was ¥945,799,422.97, a decrease of 29.36% compared to ¥1,338,882,990.74 in 2020[20]. - The net profit attributable to shareholders in 2021 was ¥350,951,064.21, a significant increase of 1,096.77% from ¥29,324,801.54 in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥148,479,133.39, reflecting a decline of 601.82% compared to -¥21,156,331.68 in 2020[20]. - The company's total assets increased by 23.47% to ¥3,065,517,046.80 at the end of 2021, up from ¥2,482,760,796.58 at the end of 2020[20]. - The basic earnings per share for 2021 was ¥1.13, representing a growth of 1,155.56% from ¥0.09 in 2020[20]. - The weighted average return on net assets was 18.11% in 2021, an increase of 16.48 percentage points from 1.63% in 2020[20]. - The net cash flow from operating activities was -¥12,533,851.80 in 2021, worsening by 178.09% from -¥4,507,046.05 in 2020[20]. - The company reported a total of ¥499,430,197.60 in non-recurring gains in 2021, compared to ¥50,481,133.22 in 2020[26]. - The total operating revenue for 2021 was approximately ¥945.8 million, a decrease of 29.36% compared to ¥1.34 billion in 2020[48]. - The pharmaceutical sector accounted for 95.14% of total revenue, generating ¥899.8 million, down 21.47% from the previous year[48]. Dividends and Share Capital - The company reported a cash dividend of 3.20 RMB per 10 shares (including tax) based on a total share base of 309,784,867 shares after repurchase[4]. - The company has a total share capital of 316,600,050 shares, with 6,815,183 shares repurchased[4]. - The company implemented a cash dividend policy, distributing a total of 99,131,157.44 CNY (including tax), which accounted for 100% of the total profit distribution[167]. - The cash dividend per 10 shares was set at 3.2 CNY (including tax), based on a total share capital of 316,600,050 shares, after deducting repurchased shares[168]. Business Operations and Strategy - The company has not changed its main business since its listing, indicating stability in operations[18]. - The company operates several wholly-owned subsidiaries, enhancing its market presence and operational capabilities[11]. - The company is actively involved in the development of innovative products and manufacturing upgrades to meet the evolving market demands[29]. - The company has a diverse product line covering various therapeutic areas, including neurological, cardiovascular, and anti-tumor diseases, which supports its vertical integration strategy[35]. - The company is focusing on developing new business lines, including animal drugs and health products, to create new profit growth points[46]. - The company has established a nationwide marketing system to adapt to intensified competition due to ongoing pharmaceutical reforms and policies[115]. - The company aims to enhance operational efficiency by focusing on projects with quicker returns amid industry challenges[96]. Research and Development - The company invested CNY 99.92 million in R&D during the reporting period, focusing on overcoming technical challenges and advancing projects like the consistency evaluation of generic drugs[41]. - The company employs 290 R&D personnel, accounting for approximately 19.09% of its total workforce, emphasizing its commitment to innovation and technology[37]. - Three products, including Ammonium Bromide Injection and Ondansetron Injection, successfully passed the consistency evaluation, enhancing the company's market position[41]. - New products such as the sodium omeprazole injection and the sodium chloride injection have been submitted for market approval, expected to create new growth points[65]. Market and Industry Trends - The pharmaceutical industry in China is experiencing a strong demand due to factors such as an aging population and increased healthcare awareness, with a long-term growth trend expected[28]. - The government aims for an average annual growth rate of over 8% in revenue and profit for the pharmaceutical industry over the next five years, emphasizing innovation and international development[29]. - The national medical insurance catalog was updated in December 2021, indicating a more scientific and standardized approach to drug inclusion[28]. Risk Management - The company faces risks including industry policy risks, drug research and development risks, and fluctuations in raw material prices[4]. - The company is actively managing risks related to raw material price fluctuations and supply interruptions by monitoring market trends and securing procurement agreements[117]. Governance and Compliance - The company has established a robust internal audit system to effectively control risks and ensure compliance[131]. - The company has a comprehensive internal management and control system tailored to its development needs[138]. - The company has established independent financial accounting departments and maintains independent bank accounts, ensuring no interference from controlling shareholders in financial decisions[136]. - The company has conducted 6 shareholder meetings during the reporting period, ensuring compliance with governance regulations[124]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with specific emissions data reported for various pollutants[179]. - The total emissions of sulfur dioxide were reported at 11,377.4 kg, within the regulatory limit of 49,280 kg[179]. - The company has implemented measures to ensure compliance with environmental standards, with no instances of exceeding discharge limits reported[179]. - The company has invested over 10 million yuan in environmental protection since its establishment, with 1.39 million yuan spent in 2021 for pollution detection and maintenance of environmental facilities[196]. Employee Management - The total number of employees at the end of the reporting period was 1,519, with 1,156 in the parent company and 363 in major subsidiaries[161]. - The employee training program included systematic internal training and external training to enhance technical skills and management capabilities[164]. - The company maintained a competitive salary policy, with fixed salaries ensuring stable income and performance-based incentives to motivate employees[162]. - The total number of technical personnel was 658, highlighting a strong emphasis on technical expertise within the workforce[161].